CEO: Christian S. Schade
Aprea AB is a Swedish biotech company focusing on discovery and development of novel anticancer compounds targeting the tumor suppressor protein p53. Aberrations in p53 are common in many various cancer forms and are associated with increased resistance to standard chemotherapy and thus poor prognosis. Aprea is a Karolinska Development AB (publ) portfolio company. The other main owners are Industrifonden, Östersjöstiftelsen, Praktikerinvest and KD Co-Investment Fund KB.
APR-246 has been developed based on results from researcher at the Karolinska Institutet. The researchers have discovered that the substance is more efficacious in cancer cells than normal cells, which indicates that it could produce significantly fewer side effects than conventional cancer treatments. By reactivating the tumor suppressor protein p53 the compound induces the cellular suicide program that eliminates the cancer cells. This has been shown in both in vitro laboratory studies and animal in vivo studies with good results. A unique characteristic of the substance is that it can activate p53 even when the gene is mutated. Cancers with mutated p53 are often more resistant to conventional treatment.